In addition to commercial cell therapy CDMOs, there are other industry players that support the cell therapy industry, including academic and medical CDMOs. While these groups do contribute to the cell therapy CDMO market, their manufacturing capabilities are limited in scale and best suited to small, early-stage clinical trials. [Read more…]
Changes in Ownership and Management Structure of Grand Bahama-Based Adult Stem Cell and Regenerative Medicine Center Signal Expansion and Growth
FREEPORT, GRAND BAHAMA, JULY 26, 2017 — Vincent R. Burton, MBBS, FRCA, has been appointed President of Okyanos Center for Regenerative Medicine, which is licensed by the Bahamas’ National Stem Cell Ethics Committee (NSCEC).
Dr. Burton received his Bachelor of Medicine, Bachelor of Surgery degree (MBBS) from the University of the West Indies. He went on to complete residency training in the United Kingdom at Queen’s Hospital of Staffordshire, Norfolk and Norwich University Hospital as well as Cambridge University’s Addenbrooke’s Hospital. He is a Fellow of the Royal College of Anaesthetists (FRCA) and has served as Chief Anesthesiologist at Okyanos since the center opened in 2014. [Read more…]
Traditionally, the contract development and manufacturing organization (CDMO) market was for pharmaceutical services, including drug compound development and manufacturing. Over time, many pharmaceutical companies expanded into offering services for biopharmaceuticals and biologics as well, and a companies went as far as to specialize in cell therapy CDMO services. [Read more…]
Houston-Based Life Sciences Firm Adds Bahamas Adult Stem Cell Therapy Company to Portfolio
HOUSTON, July 25, 2017 — Black Beret Life Sciences LLC has finalized the acquisition of Okyanos Operating Company, Ltd., a state-of-the-art adult stem cell and regenerative medicine center based in Freeport, Grand Bahama.
A contract development and manufacturing organization (CDMO), is a company that serves cell therapy companies on a contract basis. Common cell therapy CDMO services include cell therapy product development, manufacturing, clinical trial support, and commercial supply.
CDMOs allows cell therapy companies to outsource aspects of their business, which can support:
- Speed to market
- Adding technical expertise without overhead costs
- Cost efficiencies